Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

3.690 -0.010 (-0.27%)

Delayed Quote Updated: 12:12 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

85 Biggest Movers From Yesterday ↗

August 11, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...

Via Benzinga

Analyzing Fulcrum Therapeutics's Unusual Options Activity ↗

August 10, 2021

On Tuesday, shares of Fulcrum Therapeutics (NASDAQ:FULC) ...

Via Benzinga

Earnings Scheduled For August 10, 2021 ↗

August 10, 2021

Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 10, 2021

Gainers CohBar (NASDAQ:CWBR) shares incr...

Via Benzinga

FULC Stock: The Trial News Sending Fulcrum Therapeutics Skyrocketing ↗

August 10, 2021

Shares of FULC stock are skyrocketing higher today on reports of positive results for the company's sickle cell treatment trial.

Via InvestorPlace

Mid-Afternoon Market Update: 3D Systems Surges On Upbeat Earnings; Katapult Shares Drop ↗

August 10, 2021

Toward the end of trading Tuesday, the Dow traded up 0.49% to 35,274.95 while the NASDAQ fell 0.41% to 14,799.03. The S&P also rose, gaining 0.18% to 4,440.12. The U.S. has...

Via Benzinga

Topics Stocks

Why Fulcrum Therapeutics Shares Are Soaring Today ↗

August 10, 2021

Fulcrum Therapeutics Inc (NASDAQ: FULC) is surging higher Tuesday after the company reported results from its Phase 1 study of FTX-6058 for sickle cell disease showed...

Via Benzinga

Fulcrum Stock Nearly Triples — Why Shares Went Gangbusters On Sickle Cell Drug ↗

August 10, 2021

Fulcrum Therapeutics unveiled positive results for its sickle cell disease drug, and the biotech stock more than doubled to a 13-month high.

Via Investor's Business Daily

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Mid-Day Market Update: Crude Oil Rises Over 3%; comScore Shares Plummet ↗

August 10, 2021

Midway through trading Tuesday, the Dow traded up 0.37% to 35,231.28 while the NASDAQ fell 0.62% to 14,767.78. The S&P also fell, dropping 0.01% to 4,432.24. The U.S. has the...

Via Benzinga

Topics Stocks

54 Stocks Moving In Tuesday's Mid-Day Session ↗

August 10, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...

Via Benzinga

Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today ↗

August 10, 2021

A positive trial readout suggests the company's new drug discovery engine has more potential than expected.

Via The Motley Fool

Mid-Morning Market Update: Markets Open Higher; Sysco Tops Q4 Views ↗

August 10, 2021

Following the market opening Tuesday, the Dow traded up 0.47% to 35,266.74 while the NASDAQ rose 0.04% to 14,866.20. The S&P also rose, gaining 0.28% to 4,444.54. The U.S. has...

Via Benzinga

Topics Stocks

Fulcrum Shares Are Trading Higher As Candidate For Inherited Blood Disorders Shows Proof Of Mechanism, Biology In Early-Stage Study ↗

August 10, 2021

Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers. FTX-6058 is...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 10, 2021

Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5...

Via Benzinga

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗

August 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 21, 2021

Gainers Chembio Diagnostics (NASDAQ:CEMI) stock rose 189.72% to $5.97 during Wednesday's regular session. Trading volume for Chembio Diagnostics's stock is 265.3...

Via Benzinga

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs ↗

June 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 29, 2021

Gainers Brickell Biotech (NASDAQ:BBI) stoc...

Via Benzinga

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗

June 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

Via Talk Markets

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...

Via Benzinga

Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation ↗

May 12, 2021

The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral...

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.